This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Regulatory pathway and agency interaction: The EU vs the US
Published on: Jun 20th, 2022
The introduction of a new medicinal product to the US and European market follows a complex process that may extend many years from the initial discovery through to the FDA and EMA approval and market launch. There are many factors during the product development that impact the success of drug approval and launch, and a thorough understanding of the US and EU regulations and requirements is often underrated. The drug development process is becoming increasingly specialized and the regulatory pathway that works for one program may not work or be applied to another program for the same indication and this also applies to the regions considered.
In this webinar VCLS regulatory science experts analyse the similarities and differences between the US and European health agencies in terms of the review team, meeting opportunities, clinical trial submissions (IND vs. CTA), discuss ways and the right timing to interact with the FDA and EMA and their expedited programs.
SAMPLE OF THE WEBINAR
Webinar “Regulatory pathway and agency interaction: The EU vs. the US” – short version EN
Access the full webinar replay now
Fill in the form to download the content